

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-16 (CANCELED)

17. (CURRENTLY AMENDED) A tumor cell composition consisting essentially of:
an isolated primary tumor cell modified to express a B7-2 protein and at least one additional immune modulator, wherein said isolated primary tumor cell expressing B7-2 and at least one additional immune modulator has been irradiated.
18. (PREVIOUSLY PRESENTED) The tumor cell composition according to claim 17, wherein said at least one additional immune modulator is a cytokine protein.
19. (PREVIOUSLY PRESENTED) The tumor cell composition according to claim 18, wherein said cytokine protein is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interferon-gamma, and tumor necrosis factor-alpha.
20. (PREVIOUSLY PRESENTED) The tumor cell composition according to claim 18, wherein said cytokine protein is granulocyte-macrophage colony stimulating factor.

Claims 21-50 (CANCELED)

51. (NEW) The tumor cell composition according to claim 17, wherein said tumor cell composition is prepared by a process comprising:
 - infecting primary tumor cells with a recombinant retrovirus vector encoding both B7-2 and an additional immune modulator;
 - selecting the infected primary tumor cells for expression of B7-2 and the additional immune modulator; and

irradiating said selected primary tumor cells expressing B7.2 and at least one additional immune modulator.

52. (NEW) A tumor cell composition comprising an isolated autologous primary tumor cell transfected to express a B7-2 protein and GM-CSF, wherein said isolated autologous primary tumor cell expressing B7-2 and GM-CSF has been irradiated.